THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Salajka, Frantisek [1 ]
Pesek, Milos [2 ]
Krejci, Jana [3 ]
Skrickova, Jana [4 ]
Zatloukal, Petr
Koubkova, Leona
Grygarkova, Ivona
Hrnciarik, Michal [1 ]
Sticha, Michal [5 ]
机构：
[1] Univ Hosp, Dept Pneumol, Bulovka, Czech Republic
[2] Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[3] Charles Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[4] Univ Hosp Brno, Dept Resp Dis & Tb, Brno, Czech Republic
[5] Masaryk Univ, CS-60177 Brno, Czech Republic
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; erlotinib; clinical predictors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1293 / S1294
页数：2
相关论文
共 50 条
  • [21] Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Cohen, Martin H.
    Johnson, John R.
    Chattopadhyay, Somesh
    Tang, Shenghui
    Justice, Robert
    Sridhara, Rajeshwari
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (12) : 1344 - 1351
  • [22] Experience with erlotinib in the treatment of non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 146 - 163
  • [23] Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib
    Cedres, Susana
    Prat, Aleix
    Martinez, Pablo
    Pallisa, Esther
    Sala, Gemma
    Andreu, Jordi
    del Campo, J. M.
    Quispe, Isela
    Baselga, Jose
    Felip, Enriqueta
    LUNG CANCER, 2009, 66 (02) : 257 - 261
  • [24] COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND
    Prasongsook, Naiyarat
    Jaruhathai, Sureerat
    Maoleekulpairoj, Savitree
    Sooksriwong, Chaoncin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1245 - S1246
  • [25] Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer
    Emoto-Yamamoto, Y.
    Iida, S.
    Kawanishi, T.
    Fukuoka, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (02) : 232 - 239
  • [26] Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials
    Gao, Hui
    Ding, Xin
    Wei, Dong
    Cheng, Peng
    Su, Xiaomei
    Liu, Huanyi
    Aziz, Fahad
    Wang, Daoyuan
    Zhang, Tao
    ANTI-CANCER DRUGS, 2011, 22 (09) : 842 - 852
  • [27] C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib
    Cstoth, Ingrid
    Anthoine, Geraldine
    Berghmans, Thierry
    Mascaux, Celine
    Paesmans, Marianne
    Sculier, Jean-Paul
    Meert, Anne-Pascale
    ANTICANCER RESEARCH, 2011, 31 (01) : 281 - 285
  • [28] Use review of Erlotinib in advanced non-small cell lung cancer
    Alvarez-Payero, M.
    Ucha-Samartin, M.
    Martinez-Lopez-de-Castro, N.
    Campelo-Sanchez, E.
    Alvarez-Seoane, J.
    Vazquez-Lopez, C.
    Inaraja-Bobo, M. T.
    Perez Parente, D.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 438 - 438
  • [29] ADVANCED NON-SMALL CELL LUNG (NSCLC) IN YOUNG PATIENTS (≤ 40 YEARS): TREATMENT AND CLINICAL OUTCOMES
    Caffo, Orazio
    Ceribelli, Anna
    Demarinis, Filippo
    Gregore, Vanesa
    Novello, Silvia
    Bearz, Alessandra
    Bonetti, Andrea
    Grossi, Francesco
    Murgia, Viviana
    Ricciardi, Serena
    Rosetti, Francesco
    Tiseo, Marcello
    Vavala, Tiziana
    Galligioni, Enzo
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1223 - S1224
  • [30] IMPACT AND SAFETY PROFILE OF ERLOTINIB TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER - A SMALL PROSPECTIVE STUDY
    Mazilu, Laura
    Iorga, Polixenia
    Suceveanu, Andra-Iulia
    Parepa, Irinel
    Suceveanu, Adrian
    Tofolean, Doina
    Adam, Tatiana
    Jinga, Dan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1234 - S1234
12345